ClinicalTrials.gg
CompletedNCT01423305BF-BLOCKUpdated Oct 21, 2011

Phase I Pharmacokinetic Study (BF-BLOCK)

A Phase 1 interventional study of Budesonide/formoterol capsule. and Budesonide/formoterol capsule for oral adm. in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-21.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
17th of 19
20 · median 72
Started
2011
with 2 others
Phase 1
12 of 21
none open now
Registered
5th of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2011, is one of 12 in phase 1, and was the 5th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females aged 18-60 years.
  2. Normal weight at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of a cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  3. Any condition requiring concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  4. Known to the active substance(s) or the of the drug.
  5. Pregnant or lactating females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A

    Budesonide/formoterol capsule (Orion Pharma) for oral administration.

    Drug: Budesonide/formoterol capsule.

  • Experimental
    Treatment B

    Budesonide/formoterol capsule (Orion Pharma) for oral administration.

    Drug: Budesonide/formoterol capsule for oral adm.

Interventions

  • DrugBudesonide/formoterol capsule.

    Oral administration with concomitant charcoal.

  • DrugBudesonide/formoterol capsule for oral adm.

    Oral administration without concomitant charcoal.

06

What researchers measure

Primary outcomes

  1. The evaluation of primary pharmacokinetic variable AUCt

    The evaluation of primary pharmacokinetic variable AUCt of this study will be based on statistical methods appropriate for crossover design.

    Time frame: 4 weeks

Secondary outcomes

  1. Pharmacokinetic variables

    Cmax

    Time frame: 4 weeks

  2. Pharmacokinetic variable

    tmax

    Time frame: 4 weeks

07

Study locations

1 site
  • Clinical Reseach Services Turku (CRST)
    Turku, 20520, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2011
First posted
Aug 25, 2011
Start
Aug 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Oct 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01423305
Responsible party
Sponsor
First posted
Aug 25, 2011
Start date
Aug 2011
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Oct 21, 2011

Study contacts

Mika Scheinin, M.D.Ph.D
principal investigator · Clinical Research Services Turku Finland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion